1. Generics Bulletin
  2. >>Policy & Regulation

IGBA Aims To Take The Fight To Originators On Trade Deals

 
• By Aidan Fry

 With a permanent structure in place and a trade principles paper recently updated, the IGBA believes it is well placed to argue the case for promoting accessible medicines in international trade negotiations versus the interests of the originator industry.

Logistics
IGBA has laid out a list of basic principles on access to medicines that should be considered when negotiating free trade agreements • Source: Shutterstock

The global off-patent drugs industry plans to step up its efforts to counter the originator sector’s bid to use free trade agreements to push for more generous intellectual-property protections. To that end, the International Generic and Biosimilar Medicines Association (IGBA) has just published an updated version of a report on trade principles and proposals that it first produced in 2015.

During a session on trade at the IGBA’s recent joint annual conference with Medicines for Europe, the chair of the IGBA’s international trade and intellectual property committee, Jim Keon, struck a positive tone on

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Conferences